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Oncogenes usually increase their normal function when activated. However, seemingly oncogenic mutations
in IDH1 and IDH2 reduce their native enzyme activity. In this issue of Cancer Cell, Ward et al. pin down a
neomorphic enzyme activity as a possible oncogenic function for these alterations.IDH1 and IDH2 are the NADP+-dependent
isocitrate dehydrogenases, which cata-
lyze the oxidative decarboxylation of iso-
citrate to a-ketoglutarate (a-KG). IDH1
resides in the cytoplasm and peroxisome,
whereas IDH2 resides in the mitochondria.
The IDH1 R132 mutations were found
to occur frequently in gliomas in a whole-
genome exon-sequencing analysis (Par-
sons et al., 2008), and a high frequency
of the same mutations were later discov-
ered in AML (Mardis et al., 2009). Interest-
ingly, some gliomas contain IDH2 R172
mutations, albeit less frequently than
IDH1 mutations (Yan et al., 2009). IDH2
R172 is analogous to IDH1 R132, and
both play a role in binding isocitrate in
the enzyme active site. A spectrum of
missense mutations is observed at IDH1
R132 and IDH2 R172 in cancer. For
instance, common IDH1 mutations in-
clude R132H and R132C, and common
IDH2 mutations include R172K and
R172M. Almost all reported cases of
IDH1 and IDH2 mutation have been
heterozygous, and inactivating alterations
such as frameshifts, deletions, and non-
sense mutations have not been observed
for these genes in cancer. This genetic
evidence led to early speculation that the
IDH mutations confer the enzymes with
an oncogenic gain of function.
Initial functional studies of IDH1 and
IDH2 mutations appeared to stand in
contrast to the gain-of-function hypoth-
esis. These data revealed that the muta-
tions reduce the ability of IDH1 and IDH2
to convert isocitrate to a-KG (Yan et al.,
2009). Furthermore, IDH1 R132 mutants
can, in a dominant-negative manner,
inhibit wild-type IDH1 activity in vitro
(Zhao et al., 2009). This led to the specu-
lation that IDH1 and IDH2 are tumorsuppressors with a propensity to develop
dominant-negative point mutations. Re-
cently, Dang et al. reignited the debate
over the nature of the IDH mutations by
showing that the IDH1 R132 mutants
gain the neomorphic enzymatic activity
to reduce a-KG to R()-2-hydroxygluta-
rate (2HG, Figure 1) (Dang et al., 2009).
So which functions of the IDH muta-
tions—dominant-negative activity or neo-
morphic enzyme activity—are important
in cancer?
In this issue of Cancer Cell, Ward et al.
find clues to help answer this question
by turning to IDH2. Given their structural
resemblance and similar distribution in
cancer, the IDH2 R172 mutations prob-
ably function similarly to the IDH1 R132
mutations, but IDH2 mutations have not
previously been found in leukemias.
Furthermore, neither dominant-negative
activity nor 2HG production have been
investigated extensively for these IDH2
mutants.
Ward and colleagues are among the first
to show that IDH2 R172 mutations also
occur in AMLs (Green and Beer, 2010;
Gross et al., 2010; Ward et al., 2010), and
that a novel IDH2 mutation, R140Q, also
repeatedly occurs in this type of cancer
(Green and Beer, 2010; Ward et al.,
2010). Together with the IDH1 R132 and
IDH2 R172 mutations, the IDH mutations
occur in a significantly larger proportion
of AMLs than previously thought, with
23% of AML cases mutated in this study.
Curiously, IDH2 R140 mutations or the
equivalent IDH1 R100 mutations had not
previously been found in a large number
of gliomas (Yan et al., 2009). This under-
scores a striking, but unexplained, dif-
ference in the IDH mutation spectrum
between gliomas and leukemias.Cancer Cell 1This group provides support for the idea
that IDH1 and IDH2 are proto-oncogenes,
with neomorphic enzyme activity as their
shared oncogenic function. They show
that, like IDH1 R132 mutations, IDH2
R140 and R172 mutations lead to the
production of 2HG. In the wild-type
enzymes, the IDH1 R132, IDH2 R172,
and IDH2 R140 residues all form hydrogen
bonds with the b-carboxyl of isocitrate.
Mutation of these residues presumably
favors conversion of a-KG to 2HG, which
resembles isocitrate but lacks this b-
carboxyl (Figure 1). This finding points to
the neomorphic enzyme activity to convert
a-KG to 2HG as one possible oncogenic
mechanism for all of the IDH1 and IDH2
mutations observed in cancer, rather than
an unimportant side effect of the IDH1
mutations. Moreover, Ward et al. suggest
that IDH1 and IDH2 act as oncogenes
rather than tumor suppressors by showing
that siRNA knockdown of IDH1 or IDH2
results in lower glioma cell growth in vitro,
the opposite of what might be expected
for knockdown of a tumor suppressor.
Though the neomorphic enzyme ac-
tivity of the IDH mutants probably influ-
ences cancer or precancer cell biology,
the downstream effects of this activity
remain unknown. Most attention has
been focused on the possibility that 2HG
acts as an oncometabolite, either as a
general mutagen or by modulating a spe-
cific cellular process. For instance, IDH1
R132H can upregulate the cancer-associ-
ated transcription factor HIF-1a in vitro
(Zhao et al., 2009). On one hand, it has
been speculated that 2HG could mediate
this upregulation by inhibiting prolyl
hydroxylases and releasing HIF-1a from
prolyl hydroxylase-dependent downregu-
lation (Frezza et al., 2010). On the other7, March 16, 2010 ª2010 Elsevier Inc. 215
Figure 1. Mutations in the Active Site of IDH1 and IDH2 Lead
to a Neomorphic Enzyme Activity
Wild-type IDH1 and IDH2 normally catalyze the conversion of isocitrate to
a-KG (left reaction) and at the same time reduce NADP+ to NADPH and
produce CO2. R132 in wild-type IDH1, as well as R140 and R172 in wild-
type IDH2, form hydrogen bonds with the b-carboxyl (green) of isocitrate.
Cancer-derived mutations affecting these residues cause the enzymes to
instead convert a-KG to 2HG while at the same time oxidizing NADPH to
NADP+ (right reaction). 2HG and isocitrate share an identical chemical back-
bone but differ solely in the presence of the b-carboxyl on isocitrate, but not
2HG. IDH1 R132, IDH2 R140, and IDH2 R172 mutation apparently favors
conversion to 2HG rather than isocitrate given that 2HG lacks this group.
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of neomorphic IDH1 and
IDH2 enzyme activity, such
as metabolic flux away from
a-KG, a central cellular met-
abolite, and alteration of the
cellular NADP+/NADPH bal-
ance, could also have far-
reaching metabolic effects on
the cell. Future studies in-
volving animal models, rig-
orous enzyme study, and
interrogation of relevant cell
lines will be needed to deter-
mine the consequences of
IDH mutations on cancer cell
development.
Already, 2HG has shown
promise as a cancer bio-
marker: Ward and colleagues
used 2HG as a marker to iden-
tify AML samples to screen for
novel IDH1 and IDH2 muta-
tions. This approach led to
their discovery of the IDH2
R140 alteration and may play
a role in the diagnosis of
patients with new or relapsed
cases of AML or glioma. If2HG levels are high in the serum, urine,
or cerebrospinal fluid of patients with
IDH-mutated cancers, measurement of
this metabolite could be used as an
adjunct to histopathological analysis or
even in place of a more invasive proce-
dure.
Several features of the IDH1 and IDH2
mutations make their study exciting for
the future development of therapeutics.
First, in contrast to oncogenic signaling
molecules that have proven difficult to
target with small compounds, the active
sites of metabolic enzymes are probably
amenable to such targeting. Second,
IDH mutations appear early in cancer
development compared to other genetic216 Cancer Cell 17, March 16, 2010 ª2010 Ealterations, and they are found in cancers
that are composed of relatively undiffer-
entiated cells. On the basis of this, Ward
and colleagues speculate that the muta-
tions could mediate a block in cellular
differentiation that leads to carcinogen-
esis. If true, a therapeutic strategy aimed
at modulating cell differentiation path-
ways may aid in the treatment of these
cancers. Finally, though the mutations
occur early in cancer, the same IDH muta-
tion is always retained as gliomas prog-
ress to higher-grade tumors (Yan et al.,
2009) and in relapses of AML (Chou
et al., 2010), indicating that the mutant
enzymes could serve as stable thera-
peutic targets. If so, small molecules thatlsevier Inc.target mutated IDH enzymes
or yet-to-be-identified play-
ers in their oncogenic net-
work may be very successful
in treating these challenging
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